Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur

This Oncology program in Namur, Belgium is centered on a broad portfolio of cancer research, with studies spanning breast cancer, ovarian cancer, lung cancer, head and neck cancers, and several other solid and blood cancers. The trials mainly aim to test new therapies, improve treatment combinations, and refine care for patients with advanced or high-risk disease.

• Key focus on neoplasms and advanced solid tumors, including efforts to improve disease control and survival
• Research in breast cancer covers early-stage, metastatic, HER2-positive, HER2-negative, and triple-negative disease
• Studies in ovarian, endometrial, and cervical cancer often explore better treatment strategies for recurrent or high-risk disease
• Trials in lung cancer examine targeted and immune-based approaches for non-small cell and small cell subtypes
• Additional work includes head and neck cancer, urothelial carcinoma, melanoma, and gastrointestinal cancers

With 98 clinical trials and 77 investigators, the site supports a highly active research environment. Many studies at this hospital focus on evaluating new treatment options, comparing them with current standard care, and supporting more personalized cancer treatment.

A major part of the research portfolio is dedicated to breast cancer, including HER2-positive, HER2-negative, hormone receptor-positive, and triple-negative breast cancer. These trials are designed to improve outcomes in both early and metastatic settings, especially for patients at higher risk of recurrence or with limited treatment options.

• Research in early breast cancer focuses on reducing recurrence after surgery and standard treatment
• Metastatic disease studies aim to improve disease control and extend progression-free survival
• Several trials explore targeted and immune-based approaches for HER2-positive breast cancer
• Other studies address triple-negative breast cancer and ESR1- or PIK3CA-altered disease
• Overall purpose: testing new treatment strategies and refining therapy selection for different breast cancer subtypes

The work at Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur reflects a strong commitment to personalized breast cancer care, from adjuvant treatment to advanced disease management.

The site also has extensive activity in ovarian cancer and related gynecologic cancers, including endometrial cancer and cervical cancer. These studies focus on patients with advanced, recurrent, or treatment-resistant disease, where the goal is often to improve survival and delay relapse.

• Trials in ovarian cancer evaluate new ways to improve outcomes in advanced, platinum-resistant, and recurrent disease
• Endometrial cancer studies examine maintenance and adjuvant approaches to reduce recurrence risk
• Cervical cancer research includes treatment strategies for locally advanced, recurrent, and metastatic disease
• Some studies focus on patients with molecular features such as MMRd or BRCA alterations
• Purpose: improving treatment effectiveness while tailoring care to tumor biology

This gynecologic oncology portfolio is a notable part of the research activity at the Namur hospital site, with a strong emphasis on advanced disease settings.

Another important area is lung cancer, especially non-small cell lung cancer and selected small cell lung cancer populations. The trials are exploring new targeted therapies, immune-based combinations, and treatment strategies for patients with advanced or metastatic disease.

• Non-small cell lung cancer studies include both untreated and previously treated advanced disease
• Some research targets specific genetic subtypes such as RET fusion-positive or KRAS G12C-mutated disease
• Trials also examine approaches for metastatic and locally advanced thoracic cancers
• Research aims to improve response rates, survival, and treatment durability
• Overall theme: testing more precise and potentially more effective therapies for lung cancer

This thoracic oncology work supports the broader cancer research mission of Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur.

The trial portfolio extends beyond the most common cancer types to include head and neck cancers, esophageal cancer, gastroesophageal junction cancer, colorectal cancer, pancreatic cancer, and urothelial carcinoma. These studies often focus on difficult-to-treat or metastatic disease, where new options are especially needed.

• Head and neck squamous cell carcinoma research includes recurrent, metastatic, and locally advanced disease
• Digestive system cancers include esophageal, gastroesophageal junction, colorectal, rectal, and pancreatic tumors
• Urothelial carcinoma studies explore new treatment combinations for advanced disease
• Additional work includes melanoma and other advanced solid tumors
• Purpose: improving disease control, survival, and treatment options in cancers with high unmet need

This diverse research area shows how the site contributes to both common and less frequent oncology indications through clinical trial participation.

In addition to cancer-focused studies, the site participates in trials involving hematologic diseases, immune system disorders, and selected metabolic or nutritional conditions. These projects broaden the research profile beyond solid tumors and support care for patients with complex medical needs.

• Hemic and lymphatic diseases include lymphoma and higher-risk myelodysplastic syndrome
• Immune system disease research includes inflammatory conditions such as ulcerative colitis and Crohn's disease
• Some studies address type 1 diabetes and other chronic conditions linked to long-term disease management
• Research goals include evaluating treatment benefit, safety, and longer-term disease control
• These trials add breadth to the site’s overall clinical research activity

Together, these studies highlight the site’s wide therapeutic reach across oncology and selected non-oncology disease areas.